UK markets open in 2 hours 2 minutes
NIKKEI 225
37,738.13 -721.95 (-1.88%) HANG SENG
17,295.93 +94.66 (+0.55%) CRUDE OIL
82.92 +0.11 (+0.13%) GOLD FUTURES
2,327.00 -11.40 (-0.49%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,591.03 -2,151.12 (-4.00%)
Immunovia AB (publ) (0G8X.L)
LSE - LSE Delayed price. Currency in SEK
Add to watchlist
At close: 11:13AM BST
| Previous close | 1.4680 |
| Open | 0.0000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 21,015 |
| Market cap | 270,383 |
| Beta (5Y monthly) | 2.73 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.8050 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireInvitation to Immunovia's Q1 presentation
Immunovia will publish its first quarter 2024 results on April 29, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com
PR NewswireImmunovia announces updated financial calendar
Immunovia (NASDAQ Stockholm: IMMNOV), the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection, updates its financial calendar for 2024.
PR NewswireImmunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test
Immunovia (NASDAQ Stockholm: IMMNOV), the diagnostics company with the mission to increase pancreatic cancer survival through early detection, today announces its next-generation pancreatic cancer test achieved both the primary and secondary endpoints in a model-development study.
© 2024 Yahoo. All rights reserved.